Minimal effect of long-term clonazepam on cognitive function in patients with isolated RBD.

STUDY OBJECTIVES: Despite its widespread use in patients with isolated rapid eye movement sleep behavior disorder (iRBD), the cognitive effect of clonazepam is uncertain. This study aimed to investigate effect of cumulative clonazepam on cognitive function in patients with iRBD.

METHODS: Demographic characteristics, baseline cognitive test, and most recent cognitive test information were collected retrospectively. Based on cumulative clonazepam doses, patients were classified into four subgroups: group 1 < 365 mg (1 mg * 1 year); 365 mg ≤ group 2 < 1,095 mg (1 mg * 3 years); 1,095 mg ≤ group 3 < 2,190 mg (1 mg * 6 years); and group 4 ≥ 2,190 mg. Cognitive test scores were calculated as z-scores adjusted for age, education, and sex.

RESULTS: This study included 101 patients with iRBD (63 males). Groups 1, 2, 3, and 4 had 14, 20, 32, and 35 patients, respectively. In within-group comparisons, follow-up Digit Span Backward test and the Trail Making Test A (TMT-A) scores decreased in group 3, and follow-up TMT-A and the Trail Making Test B scores decreased significantly in group 4. In the multiple regression analysis to determine influential factors on cognitive decline, cumulative clonazepam dose did not show a significant correlation with any cognitive domain. Follow-up cognitive function showed significant correlation only with baseline cognitive function.

CONCLUSIONS: Memory and executive functions tended to decline in patients with iRBD. However, there was no significant effect of cumulative clonazepam. There was no evidence that long-term use of clonazepam was related to cognitive decline in patients with iRBD.